Menu

Renaud VAILLANT

GENTILLY

En résumé

Managing Director - Technologies - International

Mes compétences :
International
Biotechnologies
Entreprenariat
Business development
Innovation
Management

Entreprises

  • THERAVECTYS - CEO and Board Member

    2010 - 2015 THERAVECTYS is a fully-integrated discovery and clinical development biotech company originating from the Pasteur Institute.

    Based on its lentiviral vector technology platform, THERAVECTYS develops innovative immunotherapies to fight cancers and infectious diseases, including a proprietary and differentiated CAR T-cell technology platform.

    Capitalizing over 15 years of fundamental research in the field of lentiviral vectors, the company has built a broad and robust intellectual property position in addition to worldwide and exclusive licenses secured from institutions including Institut Pasteur and Institut Curie.

    The company has recently successfully completed a Phase I/II confirming both safety & immunogenicity of the lentiviral vector technology. THERAVECTYS lead oncology lentivector immunotherapy will enter clinical trials in 2015 while the company’s CAR T-cell therapies are in the preclinical stage.
  • THERAVECTYS - Deputy CEO

    2010 - 2010 THERAVECTYS is a fully-integrated discovery and clinical development biotech company originating from the Pasteur Institute.

    Based on its lentiviral vector technology platform, THERAVECTYS develops innovative immunotherapies to fight cancers and infectious diseases, including a proprietary and differentiated CAR T-cell technology platform.

    Capitalizing over 15 years of fundamental research in the field of lentiviral vectors, the company has built a broad and robust intellectual property position in addition to worldwide and exclusive licenses secured from institutions including Institut Pasteur and Institut Curie.

    The company has recently successfully completed a Phase I/II confirming both safety & immunogenicity of the lentiviral vector technology. THERAVECTYS lead oncology lentivector immunotherapy will enter clinical trials in 2015 while the company’s CAR T-cell therapies are in the preclinical stage.
  • Store Electronic Systems - Director

    Argenteuil 2007 - maintenant Company founded in 1988, listed on the Euronext Stock Exchange since 2006. Headcount: 200 people.

    SES is the world leader in Electronic Shelf Labels for retailers. The SES solution uses a radio technology that enables retailers to wirelessly update prices and operations data.

    SES has developed specific solutions for every type of retail environment, including hypermarkets, supermarkets, DIY stores, electronics stores, garden centers, pharmacies and service stations.

    As of June 30th 2015, more than 9 000 stores have been deployed throughout hundreds of customers in more than 54 countries.
  • CRYOLOG - Founder, CEO and Board Member

    Nantes 2001 - 2008 CRYOLOG develops original solutions for the traceability of temperature-sensitive products.These solutions make it possible to check at a glance, and over the life span of the product, whether the storage conditions have maintained the product’s freshness.
    The products and services offered by CRYOLOG respond to the requirements of our clients’ in the agri-food, health and non-domestic catering sectors, for high performance and ease of use and implementation. These solutions also take into account the legitimate expectations of consumers who are more and more demanding in terms of the quality and the safety of products.
    The use of microbiology to model the evolution of the products being traced is a technological revolution. This technological advance, which is only offered by CRYOLOG, means that we can provide our clients with products which are precisely adapted to their requirements.

Formations